Zika (Flaviviruses)
Overview
Plain-Language Overview
Zika virus is an infection caused by a virus transmitted primarily by the bite of infected Aedes mosquitoes. It mainly affects the nervous system and can cause symptoms such as fever, rash, joint pain, and conjunctivitis. Most people experience mild illness, but the virus is especially concerning for pregnant women because it can cause serious birth defects like microcephaly in babies. The virus can also be spread through sexual contact and from mother to fetus during pregnancy. Diagnosis is usually made based on symptoms and confirmed with laboratory tests. The infection typically resolves on its own without severe complications in healthy individuals.
Clinical Definition
Zika virus infection is a mosquito-borne illness caused by the Zika virus, a member of the Flaviviridae family. The virus primarily targets the central nervous system, leading to neurological complications such as Guillain-Barré syndrome and congenital abnormalities including microcephaly in neonates. Transmission occurs mainly through the bite of infected Aedes aegypti and Aedes albopictus mosquitoes, but can also occur via sexual contact, blood transfusion, and vertical transmission. The infection is characterized by a self-limited febrile illness with rash, arthralgia, and conjunctivitis. The major clinical significance lies in its teratogenic potential and neurological sequelae. Diagnosis relies on detection of viral RNA or specific antibodies. The disease has a global public health impact due to its epidemic potential and severe fetal outcomes.
Inciting Event
Bite from an infected Aedes aegypti or Aedes albopictus mosquito is the primary initiating event.
Vertical transmission occurs when the virus crosses the placental barrier during maternal viremia.
Sexual contact with an infected individual can initiate infection in the absence of mosquito exposure.
Rarely, transmission can occur via blood transfusion or organ transplantation from infected donors.
Latency Period
The incubation period from mosquito bite to symptom onset is typically 3 to 14 days.
Congenital infection effects may manifest in utero or become apparent at birth or early infancy.
Sexual transmission incubation is similar, with symptoms developing within 1 to 2 weeks post-exposure.
Asymptomatic infections may have no clear latency period due to lack of clinical signs.
Diagnostic Delay
Symptoms are often mild and nonspecific, leading to misdiagnosis as dengue, chikungunya, or other viral illnesses.
Lack of awareness and limited access to molecular diagnostic testing in endemic areas delays confirmation.
Overlap of rash and fever with other arboviral infections complicates clinical diagnosis without laboratory support.
Asymptomatic cases and subclinical infections frequently go undetected, delaying epidemiologic recognition.
Clinical Presentation
Signs & Symptoms
Fever, usually low-grade and transient, is an early symptom.
Maculopapular rash appearing 1-2 days after fever onset is characteristic.
Arthralgia and myalgia commonly affect small joints.
Conjunctivitis without purulent discharge is a hallmark sign.
Headache and malaise are frequent but nonspecific symptoms.
History of Present Illness
Initial symptoms include low-grade fever, maculopapular rash, arthralgia, and conjunctivitis lasting 2 to 7 days.
Patients may report headache, myalgia, and malaise preceding or accompanying rash onset.
In pregnant women, symptoms may be mild or absent despite risk of fetal infection.
Neurologic complications such as Guillain-Barré syndrome can develop days to weeks after initial illness.
Congenital infection presents with microcephaly, intracranial calcifications, and developmental delay in neonates.
Past Medical History
Prior flavivirus infections such as dengue or yellow fever may influence immune response and disease severity.
History of pregnancy is critical due to risk of vertical transmission and fetal complications.
Previous exposure to mosquito-borne illnesses or travel to endemic areas increases suspicion for Zika.
Immunocompromised states may alter clinical presentation but are not well defined in Zika infection.
Family History
No known heritable genetic predisposition to Zika virus infection or severity has been identified.
Family history of congenital malformations may prompt evaluation for infectious causes including Zika.
Clusters of cases in families often reflect shared environmental exposure rather than genetic susceptibility.
No familial syndromes are directly associated with Zika virus infection.
Physical Exam Findings
Maculopapular rash predominantly on the trunk and face is a common finding.
Conjunctival injection without purulent discharge is frequently observed.
Lymphadenopathy, especially cervical, may be present.
Low-grade fever and mild arthralgia can be noted on examination.
Non-purulent conjunctivitis is a distinguishing feature from other arboviral infections.
Diagnostic Workup
Diagnostic Criteria
Diagnosis of Zika virus infection is established by detecting Zika virus RNA using RT-PCR in serum, urine, or other body fluids during the acute phase. Serologic testing for Zika-specific IgM antibodies can support diagnosis but may cross-react with other flaviviruses like dengue. Clinical suspicion is based on the presence of fever, rash, arthralgia, and conjunctivitis in an endemic area or after travel. Confirmation requires laboratory evidence of infection, with molecular testing preferred within the first week of symptom onset. In pregnant women, ultrasound findings of fetal abnormalities may prompt further testing.
Pathophysiology
Key Mechanisms
Transmission of Zika virus, a single-stranded RNA flavivirus, primarily occurs via Aedes mosquito bites leading to systemic viral replication.
Viral neurotropism causes infection of neural progenitor cells, resulting in neuronal apoptosis and impaired brain development.
Placental infection allows vertical transmission causing congenital Zika syndrome with microcephaly and other neurologic abnormalities.
Host immune response includes type I interferon activation which limits viral spread but may contribute to inflammatory tissue damage.
Cross-reactive antibodies from prior flavivirus infections can enhance viral entry via antibody-dependent enhancement in some cases.
| Involvement | Details |
|---|---|
| Organs | Brain involvement in congenital infection results in microcephaly and other neurodevelopmental defects. |
Lymph nodes are sites of viral replication and immune activation during systemic infection. | |
Eyes can be affected in congenital infection, causing chorioretinal atrophy and visual impairment. | |
| Tissues | Placental tissue is a key site for Zika virus transmission from mother to fetus, leading to congenital infection. |
Neural tissue is affected by viral replication causing neuronal death and developmental abnormalities. | |
Skin tissue serves as the initial site of viral entry via mosquito bite and local replication. | |
| Cells | Dendritic cells are primary targets for Zika virus entry and replication, facilitating viral dissemination. |
Neural progenitor cells are infected by Zika virus, leading to impaired neurodevelopment and microcephaly in fetuses. | |
Monocytes and macrophages contribute to the immune response and viral spread during Zika virus infection. | |
| Chemical Mediators | Type I interferons are critical antiviral cytokines produced in response to Zika virus infection, limiting viral replication. |
Proinflammatory cytokines such as TNF-alpha and IL-6 mediate systemic symptoms like fever and malaise. | |
Chemokines recruit immune cells to sites of infection, contributing to inflammation and tissue damage. |
Treatments
Pharmacological Treatments
Non-pharmacological Treatments
Supportive care including hydration and antipyretics to manage fever and pain is the mainstay of treatment for Zika virus infection.
Avoidance of mosquito exposure through insect repellents and protective clothing is critical to prevent Zika virus transmission.
Pregnant women should receive close monitoring and ultrasound surveillance due to the risk of congenital Zika syndrome.
Prevention
Pharmacological Prevention
No approved antiviral medications or vaccines are currently available for Zika virus.
Experimental vaccines are under development but not yet licensed.
Use of repellents containing DEET or picaridin is recommended for prophylaxis.
Non-pharmacological Prevention
Avoidance of mosquito exposure through bed nets and protective clothing is critical.
Elimination of standing water to reduce Aedes mosquito breeding sites.
Screening and counseling of pregnant women in endemic areas to prevent congenital infection.
Safe sex practices to prevent sexual transmission of Zika virus.
Travel advisories for pregnant women to avoid endemic regions.
Outcome & Complications
Complications
Congenital Zika syndrome with microcephaly, brain calcifications, and developmental delay.
Guillain-Barré syndrome causing acute flaccid paralysis.
Ocular abnormalities including uveitis and optic neuropathy.
Miscarriage and stillbirth in infected pregnant women.
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Zika (Flaviviruses) versus Dengue Fever
Zika (Flaviviruses) | Dengue Fever |
|---|---|
Endemic in tropical regions with Aedes mosquito exposure, often rural or peri-urban | Endemic in tropical regions with Aedes mosquito exposure, often urban |
Mild fever with maculopapular rash, conjunctivitis, and arthralgia, rarely hemorrhagic | High fever with severe myalgias and retro-orbital pain, possible hemorrhagic complications |
Mild thrombocytopenia without hemoconcentration | Marked thrombocytopenia and hemoconcentration |
Positive Zika virus RNA by RT-PCR or Zika IgM serology | Positive dengue NS1 antigen or IgM serology |
Zika (Flaviviruses) versus Chikungunya Virus Infection
Zika (Flaviviruses) | Chikungunya Virus Infection |
|---|---|
Transmission by Aedes mosquitoes in tropical regions with outbreaks | Transmission by Aedes mosquitoes in tropical regions with outbreaks |
Mild fever with rash, conjunctivitis, and arthralgia without severe arthritis | Acute onset of high fever and severe polyarthritis often involving small joints |
Mild leukopenia without significant inflammatory marker elevation | Elevated inflammatory markers and lymphopenia |
Positive Zika virus RNA by RT-PCR or IgM serology | Positive chikungunya virus RNA by RT-PCR or IgM serology |
Zika (Flaviviruses) versus Rubella Virus Infection
Zika (Flaviviruses) | Rubella Virus Infection |
|---|---|
Transmitted by Aedes mosquitoes, primarily in tropical regions | Often occurs in unvaccinated children or adults, transmitted via respiratory droplets |
Mild fever with maculopapular rash and conjunctivitis without prominent lymphadenopathy | Mild fever with posterior auricular and suboccipital lymphadenopathy and rash |
Positive Zika virus RNA by RT-PCR or IgM serology | Positive rubella IgM serology or viral RNA from throat swab |
Zika (Flaviviruses) versus Parvovirus B19 Infection
Zika (Flaviviruses) | Parvovirus B19 Infection |
|---|---|
Spread by Aedes mosquitoes in tropical regions | Spread by respiratory droplets, common in children and school outbreaks |
Diffuse maculopapular rash with conjunctivitis and arthralgia | Slapped cheek rash followed by lacy reticular rash on extremities |
Mild leukopenia and thrombocytopenia without anemia | Transient anemia due to erythroid precursor suppression |
Positive Zika virus RNA by RT-PCR or IgM serology | Positive parvovirus B19 IgM serology or DNA PCR |
Zika (Flaviviruses) versus Measles Virus Infection
Zika (Flaviviruses) | Measles Virus Infection |
|---|---|
Transmitted by Aedes mosquitoes in endemic tropical areas | Highly contagious via respiratory droplets, often in unvaccinated populations |
Mild fever with rash and conjunctivitis without Koplik spots or respiratory prodrome | Prodrome of cough, coryza, conjunctivitis, Koplik spots, followed by cephalocaudal rash |
Positive Zika virus RNA by RT-PCR or IgM serology | Positive measles IgM serology or viral RNA from throat swab |